Development and Validation of a Prognostic Nomogram for HR+ HER- Breast Cancer

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol. 2003;12(1):27–34. doi:10.1097/00019606-200303000-00004
   PubMedGoogle Scholar
• Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–1747. doi:10.1093/annonc/mdr304
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi:10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Dowling RJO, Sparano JA, Goodwin PJ, et al. Toronto workshop on late recurrence in estrogen receptor-positive breast cancer: part 2: approaches to predict and identify late recurrence, research directions. JNCI Cancer Spectr. 2019;3(4):pkz049. doi:10.1093/jncics/pkz049
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi:10.1016/S0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Pan H, Gray R, Braybrooke J, et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836–1846. doi:10.1056/NEJMoa1701830
   PubMed Web of Science ®Google Scholar
• Adjuvant therapy for breast cancer. NIH Consens Statement. 2000;17:1–35.
   Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817–2826. doi:10.1056/NEJMoa041588
   PubMed Web of Science ®Google Scholar
• Gradishar WJ, Anderson BO, Abraham J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(4):452–478. doi:10.6004/jnccn.2020.0016
   PubMed Web of Science ®Google Scholar
• Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. J Clin Oncol. 2017;35(24):2838–2847. doi:10.1200/JCO.2017.74.0472
   PubMed Web of Science ®Google Scholar
• Doll KM, Rademaker A, Sosa JA. Practical guide to surgical data sets: Surveillance, Epidemiology, and End Results (SEER) Database. JAMA Surg. 2018;153(6):588–589. doi:10.1001/jamasurg.2018.0501
   PubMed Web of Science ®Google Scholar
• Hwang YS, Kim HJ, Kim J, et al. Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer. Discov Oncol. 2022;13(1):141. doi:10.1007/s12672-022-00604-z
   PubMedGoogle Scholar
• Wen N, Qiu J, Xu L, et al. Adjuvant chemotherapy guidance for pT1-3N0-1 breast cancer patients with HR(+), HER2(-) subtype: a cohort study based on the SEER database. Ann Transl Med. 2021;9(24):1779. doi:10.21037/atm-21-5937
   PubMed Web of Science ®Google Scholar
• Zhu Y, Wang J, Xu B. A novel prognostic nomogram for predicting survival of hormone receptor-positive and HER2 negative advanced breast cancer among the han-population. Front Oncol. 2022;12:918759. doi:10.3389/fonc.2022.918759
   PubMedGoogle Scholar
• Pellegrino B, Hlavata Z, Migali C, et al. Luminal breast cancer: risk of recurrence and tumor-associated immune suppression. Mol Diagn Ther. 2021;25(4):409–424. doi:10.1007/s40291-021-00525-7
   PubMed Web of Science ®Google Scholar
• Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101(10):736–750. doi:10.1093/jnci/djp082
   PubMed Web of Science ®Google Scholar
• Cho U, Park HS, Im SY, et al. Prognostic value of systemic inflammatory markers and development of a nomogram in breast cancer. PLoS One. 2018;13(7):e0200936. doi:10.1371/journal.pone.0200936
   PubMed Web of Science ®Google Scholar
• Zambelli A, Gallerani E, Garrone O, et al. Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: defining high risk of recurrence. Crit Rev Oncol Hematol. 2023;191:104104. doi:10.1016/j.critrevonc.2023.104104
   PubMed Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1):150–158. doi:10.1038/bjc.2015.183
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature07205
   PubMed Web of Science ®Google Scholar
• Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218–230. doi:10.1016/j.critrevonc.2013.03.010
   PubMed Web of Science ®Google Scholar
• Szkandera J, Absenger G, Liegl-Atzwanger B, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer. 2013;108(8):1677–1683. doi:10.1038/bjc.2013.135
   PubMed Web of Science ®Google Scholar
• Templeton AJ, Ace O, McNamara MG, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–1212. doi:10.1158/1055-9965.EPI-14-0146
   PubMed Web of Science ®Google Scholar
• Gabay C, Kushner I, Epstein FH. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448–454. doi:10.1056/NEJM199902113400607
   PubMed Web of Science ®Google Scholar
• Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13(7):499–503. doi:10.1007/s12094-011-0687-9
   PubMed Web of Science ®Google Scholar
• Lee S, Oh SY, Kim SH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13(1):350. doi:10.1186/1471-2407-13-350
   PubMedGoogle Scholar
• Smith RA, Bosonnet L, Raraty M, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–472. doi:10.1016/j.amjsurg.2007.12.057
   PubMed Web of Science ®Google Scholar
• Zou ZY, Liu HL, Ning N, Li SY, Du XH, Li R. Clinical significance of pre-operative neutrophil lymphocyte ratio and platelet lymphocyte ratio as prognostic factors for patients with colorectal cancer. Oncol Lett. 2016;11(3):2241–2248. doi:10.3892/ol.2016.4216
   PubMed Web of Science ®Google Scholar
• Asano Y, Kashiwagi S, Onoda N, et al. Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer. PLoS One. 2016;11(7):e0153459. doi:10.1371/journal.pone.0153459
   PubMed Web of Science ®Google Scholar
• Zhang M, Huang XZ, Song YX, Gao P, Sun JX, Wang ZN. High platelet-to-lymphocyte ratio predicts poor prognosis and clinicopathological characteristics in patients with breast cancer: a meta-analysis. Biomed Res Int. 2017;2017:9503025. doi:10.1155/2017/9503025
   PubMed Web of Science ®Google Scholar
• Ishii Y, Hamashima T, Yamamoto S, Sasahara M. Pathogenetic significance and possibility as a therapeutic target of platelet derived growth factor. Pathol Int. 2017;67(5):235–246. doi:10.1111/pin.12530
   PubMed Web of Science ®Google Scholar
• Jain S, Harris J, Ware J. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol. 2010;30(12):2362–2367. doi:10.1161/ATVBAHA.110.207514
   PubMed Web of Science ®Google Scholar
• Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta. 2011;1815(2):189–196. doi:10.1016/j.bbcan.2010.12.001
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2):137–148. doi:10.1016/j.immuni.2004.07.017
   PubMed Web of Science ®Google Scholar
• Kitayama J, Yasuda K, Kawai K, Sunami E, Nagawa H. Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer. Radiat Oncol. 2010;5(1):47. doi:10.1186/1748-717X-5-47
   PubMedGoogle Scholar
• Davey MG, Hynes SO, Kerin MJ, Miller N, Lowery AJ. Ki-67 as a prognostic biomarker in invasive breast cancer. Cancers. 2021;13(17):4455. doi:10.3390/cancers13174455
   PubMed Web of Science ®Google Scholar
• Louis DM, Nair LM, Vallonthaiel AG, Narmadha MP, Vijaykumar DK. Ki 67: a promising prognostic marker in early breast cancer-a review article. Indian J Surg Oncol. 2023;14(1):122–127. doi:10.1007/s13193-022-01631-6
   PubMed Web of Science ®Google Scholar
• Nielsen TO, Leung SCY, Rimm DL, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021;113(7):808–819. doi:10.1093/jnci/djaa201
   PubMedGoogle Scholar
• Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49(2):166–171. doi:10.1016/j.pathol.2016.11.006
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(8):1194–1220. doi:10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• Turner BM, Skinner KA, Tang P, et al. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol. 2015;28(7):921–931. doi:10.1038/modpathol.2015.50
   PubMed Web of Science ®Google Scholar
• Chin-Lenn L, De Boer RH, Segelov E, et al. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable. Asia Pac J Clin Oncol. 2018;14(6):410–416. doi:10.1111/ajco.13075
   PubMed Web of Science ®Google Scholar
• McVeigh TP, Kerin MJ. Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer. Breast Cancer. 2017;9:393–400. doi:10.2147/BCTT.S109847
   PubMedGoogle Scholar
• Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China. Lancet Oncol. 2014;15(7):e279–e289. doi:10.1016/S1470-2045(13)70567-9
   PubMed Web of Science ®Google Scholar